Design of insulin analogues for meal-related therapy.
The human insulin in replacement therapy has a hexameric structure. Hexamerization of the insulin molecule facilitates biosynthesis and beta-cell storage of insulin, but is unnecessary for biologic activity and appears to contribute to delayed absorption of exogenous insulin from the subcutis. Insulin analogues with reduced self-association that are produced through recombinant DNA techniques have been shown to have in vivo activity comparable to that of human insulin and absorption kinetics characterized by higher and more constant rates of disappearance from the subcutaneous injection site. In preliminary studies in patients receiving insulin therapy, monomeric insulin analogues have been found to provide glycemic control in the postprandial period that is at least equivalent to that of human insulin. Findings in these studies suggest that the use of such analogues may provide meal-related insulin effects closer to those observed in the physiologic state by limiting excessive postprandial glucose excursions and decreasing the risk of late hypoglycemia. Banting and Best revolutionized diabetes therapy 70 years ago with the extraction of insulin from animal pancreas glands (J Lab Clin Med 7:464-472, 1922). Since that time, many refinements of the therapeutic properties of pharmaceutical preparations of the hormone have been introduced. Until recently, however, such advances have been limited to improvements in insulin purity, insulin species, and adjustment of the composition of the vehicle with respect to auxiliary substances and other additives. With the advent of recombinant DNA techniques, it has become possible to optimize the insulin molecule itself for purposes of replacement therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Novo Research Institute, Novo Nordisk A/S, Bagsvaerd, Denmark.
J
J
Brange
D000595:Amino Acid Sequence; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004435:Eating; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use*; D046911:Macromolecular Substances; D008969:Molecular Sequence Data; D011972:Receptor, Insulin / Q000378:metabolism; D013329:Structure-Activity Relationship
D001786:Blood Glucose; D007328:Insulin; D046911:Macromolecular Substances; D011972:Receptor, Insulin